Skip to content

Zenas BioPharma

US · ZBIO #2856 by market cap Listed 2024
23.85 -1.19 -4.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.6 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
119.91% +2.55pp
Institutions
195 +10
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund64.00%
VC/PE Fund23.27%
Public Company14.75%
Hedge Fund13.77%
Private Company3.86%
Individual/Insider1.46%
Government Pension Fund0.14%
Insurance Company0.12%

Top holders as of 2026-09-30

FMR 14.44% · 9.79M sh
InnoCare Pharma Limited 10.32% · 7.00M sh
Wellington Management Group 9.68% · 6.57M sh
SR One Capital Management, LP 7.43% · 5.04M sh
New Enterprise Associates, Inc. 5.93% · 4.02M sh
BlackRock 4.91% · 3.33M sh
Zebra Aggregator, LP 4.79% · 3.25M sh
Federated Hermes, Inc. 4.58% · 3.11M sh
Xencor, Inc. 4.75% · 3.10M sh
Capital Research 4.31% · 2.93M sh
Longitude Capital Management Co., LLC 3.84% · 2.61M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 49 buys · 0 sells

NameRoleStake
InnoCare Pharma Limited -- 10.32%
Leon Moulder Chairperson & CEO 0.77%
Wellington Management Group -- 10.07%
Hongbo Lu Independent Director 0.63%
Patricia L. Allen Independent Director 0.03%
Patrick Gerald Enright Independent Director 0.02%
Tim Xiao Former Independent Director 0.01%
Joseph Farmer COO, President, Principal Financial Officer & Principal Accounting Officer 0.00%
Jennifer Fox Former Chief Business Officer & CFO 0.00%
Jason Nunn Independent Director --
John Orloff Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-31 Christy Oliger Independent Director Other Derivative Acquisition +37,000 $31.98
2026-08-25 InnoCare Pharma Limited -- Initial Statement of Beneficial 0 --
2026-06-14 Leon Moulder Chairperson & CEO Other Derivative Acquisition +500,000 $18.71
2026-06-14 Patrick Gerald Enright Independent Director Other Derivative Acquisition +18,500 $18.71
2026-06-14 Jason Nunn Independent Director Other Derivative Acquisition +18,500 $18.71
2026-06-14 Jennifer Fox Former Chief Business Officer & CFO Other Derivative Acquisition +125,000 $18.71
2026-06-14 Patricia L. Allen Independent Director Other Derivative Acquisition +18,500 $18.71
2026-06-14 Joseph Farmer COO, President, Principal Financial Officer & Principal Accounting Officer Other Derivative Acquisition +175,000 $18.71
2026-06-14 John Orloff Independent Director Other Derivative Acquisition +18,500 $18.71
2026-06-14 Hongbo Lu Independent Director Other Derivative Acquisition +18,500 $18.71
2026-06-14 James Boylan Lead Independent Director Other Derivative Acquisition +18,500 $18.71
2026-06-14 Lisa von Moltke Head of Research & Development and Chief Medical Officer Other Derivative Acquisition +150,000 $18.71
2026-05-17 Leon Moulder Chairperson & CEO Open Market Acquisition +60,000 $16.88
2026-04-28 Tellus BioVentures, LLC -- Open Market Acquisition +60,000 $17.62–18.02
2026-03-30 Hongbo Lu Independent Director Open Market Acquisition +3,768 $18.63
2026-03-30 Fairmount Funds Management LLC -- Private Acquisition +150,000 $20.00
2026-03-30 Tellus BioVentures, LLC -- Open Market Acquisition +54,000 $18.23–19.31
2026-03-30 Nextbio Capital Management LP -- Private Acquisition +75,000 $20.00
2026-02-12 Patricia L. Allen Independent Director Open Market Acquisition +19,860 $23.77–26.50
2026-02-10 Nextbio Capital Management LP -- Open Market Acquisition +25,985 $22.50

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Zenas BioPharma discussion 0 comments

Add a comment